Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | TSHR | P16473 | 1/20 | 0.45 |
| ▸ | CLK1 | P49759 | 3/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | F9 | P00740 | 1/20 | 0.43 |
| ▸ | F10 | P00742 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22468777 | 1.00 | LMNA (0.50) | LMNAHDAC1KMT2AMEN1RAB9A | |
| SCHEMBL22479261 | 0.90 | HDAC1 (0.47) | LMNAHDAC1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL31232895 | 0.86 | HDAC1 (0.49) | LMNAHDAC1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL25263286 | 0.86 | HDAC1 (0.49) | LMNAHDAC1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL29065456 | 0.85 | BCL2L1 (0.58) | LMNAHDAC1KMT2ARAB9ASLC6A2 | |
| SCHEMBL22468637 | 0.84 | TDP1 (0.45) | LMNAHDAC1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL31232887 | 0.84 | CLK1 (0.46) | HDAC1KMT2AMEN1RAB9ASLC6A2 | |
| SCHEMBL17149292 | 0.84 | CLK1 (0.46) | HDAC1KMT2AMEN1RAB9ASLC6A2 | |
| SCHEMBL15698906 | 0.81 | SLC6A2 (0.46) | LMNAHDAC1KMT2ASLC6A2SLC6A3 | |
| SCHEMBL3470329 | 0.81 | LMNA (0.58) | LMNAHDAC1KMT2AMEN1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240293423-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2024-01-18 | — | — | US | disclosed |
| EP-4225303-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-08-16 | — | — | EP | disclosed |
| EP-4121055-A1 | STAT DEGRADERS AND USES THEREOF | Kymera Therapeutics, Inc. (US) | 2023-01-25 | — | — | EP | disclosed |
| WO-2022077010-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTIC, INC. (US) | 2022-04-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240016942-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | LMNA 4438/4885HDAC1 930/4885KMT2A 737/4885 |
| US-20240293423-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | LMNA 4438/4885HDAC1 930/4885KMT2A 737/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.